natgillin/translations-raw huggingface dataset:
Intermittent allergic rhinitis (presence of symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient's disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.
Intermitentni alergijski rinitis (kadar so simptomi prisotni manj kot 4 dni na teden ali manj kot 4 tedne) zdravite na podlagi ocene bolnikove pretekle anamneze v zvezi s to boleznijo.
Adults and adolescents 12 years of age and over The recommended dose is one tablet once a day with or without food.
Odrasli in mladostniki, stari 12 let in več Priporočeni odmerek je ena tableta enkrat na dan s hrano ali brez nje.
Aerius 5 mg film-coated tablets desloratadine
Aerius 5 mg filmsko obložene tablete desloratadin
Clinical efficacy and safety In a multiple dose trial, Aerius orodispersible tablets were well tolerated.
V preskušanju večkratnega odmerjanja so bolniki dobro prenašali zdravilo Aerius orodisperzibilne tablete.
Aerius 0.5 mg/ml oral solution
Aerius 0,5 mg/ml peroralna raztopina
Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnoea, pruritus, rash, and urticaria) Asthenia
Splošne težave in spremembe na mestu aplikacije pogosti zelo redki neznana pogostnost utrujenost preobčutljivostne reakcije (kot so anafilaksija, angioedem, dispneja, pruritus, izpuščaj in urtikarija) astenija
Each ml of oral solution contains 0.5 mg desloratadine.
Vsak ml peroralne raztopine vsebuje 0,5 mg desloratadina.
6.1 List of excipients sorbitol, propylene glycol, sucralose E 955, hypromellose 2910,
6.1 Seznam pomožnih snovi sorbitol, propilenglikol, sukraloza E 955, hipromeloza 2910, natrijev citrat dihidrat, naravna in umetna aroma (žvečilni gumi), brezvodna citronska kislina, dinatrijev edetat, prečiščena voda
Aerius oral solution is available in bottles of 30, 50, 60, 100, 120, 150, 225 and 300 ml, with a childproof cap. For all packages except the 150 ml bottle, a measuring spoon is provided, marked for doses of 2.5 ml and 5 ml.
Aerius peroralna raztopina je na voljo v stekleničkah po 30, 50, 60, 100, 120, 150, 225 in 300 ml, z zaporko, varno za otroke.
Aerius 2.5 mg orodispersible tablets desloratadine
Aerius 2,5 mg orodisperzibilne tablete desloratadin
Each orodispersible tablet contains 5 mg desloratadine.
Vsaka orodisperzibilna tableta vsebuje 5 mg desloratadina.
Aerius 2.5 mg orodispersible tablets
Aerius 2,5 mg orodisperzibilne tablete
Aerius orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 6 years of age and older.
Zdravilo Aerius orodisperzibilna tableta lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih, mladostnikih in otrocih, starih 6 let in več.
Aerius 5 mg orodispersible tablets
Aerius 5 mg orodisperzibilne tablete
How to store Aerius orodispersible tablet
Shranjevanje zdravila Aerius orodisperzibilna tableta
Aerius 5 mg orodispersible tablet
Aerius 5 mg orodisperzibilna tableta
The degree of accumulation of desloratadine was consistent with its half-life (approximately 27 hours) and a once daily dosing frequency.
Stopnja kopičenja desloratadina je v skladu z razpolovnim časom zdravila (približno 27 ur) in pogostnostjo odmerjanja - enkrat na dan. Biološka uporabnost desloratadina je sorazmerna odmerku v razponu od 5 mg do 20 mg.
Aerius oral solution relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 1 year of age and older.
Zdravilo Aerius peroralna raztopina lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih, mladostnikih in otrocih, starih 1 leto in več.
Aerius 2.5 mg orodispersible tablet
Aerius 2,5 mg orodisperzibilna tableta
Aerius orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
Zdravilo Aerius orodisperzibilna tableta lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih in mladostnikih, starih 12 let in več.
Aerius relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
Zdravilo Aerius lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih in mladostnikih, starih 12 let in več.
The recommended dose is 2.5 ml (½ of a 5 ml spoonful) of oral solution once a day.
Priporočeni odmerek zdravila Aerius je 10 ml (5 mg) peroralne raztopine enkrat na dan.
Aerius 5 mg orodispersible tablets desloratadine
Aerius 5 mg orodisperzibilne tablete desloratadin
What Aerius orodispersible tablet contains
Kaj vsebuje zdravilo Aerius orodisperzibilna tableta
However, if you take more Aerius orodispersible tablet than you were told to, tell your doctor, pharmacist or nurse immediately.
Pri nenamernem prevelikem odmerjanju zdravila ni pričakovati resnejših težav, kljub temu pa se v primeru, da ste zaužili več zdravila Aerius orodisperzibilna tableta, kot bi morali, takoj posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Kit for radiopharmaceutical preparation
Komplet za pripravo radiofarmaka
Reaction Buffer: vial (COP)
Prašek: viala (steklena); pufer za reakcijo: viala (COP)
Powder for solution for injection: 40 micrograms;
Prašek za raztopino za injiciranje: 40 mikrogramov; pufer za reakcijo: 1 ml
Over 40 kg
Nad 40 kg
ATCvet code: QC09BX90
Oznaka ATC vet: QC09BX90
The table below may be used for guidance.
Spodnja tabela lahko služi kot priporočilo.
FORTEKOR PLUS tablets should be administered orally, twice daily 12 hours apart (morning and evening) and approximately 1 hour before feeding.
Tablete FORTEKOR PLUS je treba dajati peroralno, dvakrat dnevno, z razmikom 12 ur (zjutraj in zvečer) in približno 1 uro pred hranjenjem.
Since this bioavailability is considerably reduced when pimobendan is administered with food or shortly thereafter, it is recommended to treat animals approximately 1 hour before feeding.
Ker se ta biološka uporabnost bistveno zmanjša, kadar se pimobendan daje s hrano ali kmalu po njej, je priporočljivo živali dati zdravilo približno 1 uro pred hranjenjem.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 08/09/2015
Datum pridobitve dovoljenja za promet: 08/09/2015
The mean plasma protein binding in vitro is 93%.
Povprečna in vitro vezava na beljakovine v plazmi je 93 %.
Do not use during pregnancy and lactation (see section 4.7).
Ne uporabite v obdobju brejosti in laktacije (glejte poglavje 4.7).
SPECIAL STORAGE CONDITIONS Store below 25 °C.
POSEBNA NAVODILA ZA SHRANJEVANJE Shranjujte pri temperaturi do 25°C.
Further metabolic pathways are phase II, glucuronides and sulfates.
Nadaljnje presnovne poti so faza II, glukuronidi in sulfati.
Iron oxide brown E172
Rjavi železov oksid E172
A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.
Pri majhnem številu psov se lahko pojavijo prehodno bruhanje, motnje koordinacije ali znaki utrujenosti.
For the full list of excipients, see section 6.1.
2 mg Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Shelf life of the veterinary medicinal product as packaged for sale: 18 months
Rok uporabnosti zdravila v pakiranju za prodajo: 18 mesecev.
After oral administration of benazepril hydrochloride alone, the systemic bioavailability is incomplete (~13%) in dogs due to incomplete absorption (38%) and first pass metabolism.
Po peroralni uporabi samega benazeprilijevega klorida je sistemska biološka uporabnost pri psih nepopolna (~ 13 %) zaradi nepopolne absorpcije (38 %) in presnove prvega prehoda.
Do not use in pregnant or lactating dogs (see section “SPECIAL WARNINGS").
Ne uporabite pri psicah v obdobju brejosti in laktacije (glejte poglavje »POSEBNA OPOZORILA«).
Any remaining half tablets should be discarded after 1 day.
Morebitne neuporabljene polovice tablet zavrzite po enem dnevu.
Benazeprilat is a highly potent and selective inhibitor of ACE, thus preventing the conversion of inactive angiotensin I to active angiotensin II and thereby also reducing the synthesis of aldosterone.
Benazeprilat je zelo močan in selektiven zaviralec ACE, in sicer prepreči pretvorbo neaktivnega angiotenzina I v aktivni angiotenzin II ter s tem tudi zmanjša sintezo aldosterona.
The tablets can be divided into equal halves.
Tablete lahko razpolovimo na enaka dela.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary In case of overdose the dog should be treated symptomatically.
4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno) V primeru prevelikega odmerjanja je treba psa zdraviti simptomatsko.
Store below 25 °C.
Shranjujte pri temperaturi do 25°C.
White and light brown oval bilayer tablets with a score line on both sides.
Bele in svetlo rjave ovalne dvoplastne tablete z zarezo na obeh straneh.
Pharmacotherapeutic group: ACE inhibitors, combinations.
FARMAKOLOŠKE LASTNOSTI Farmakoterapevtska skupina: zaviralci ACE, kombinacije.
Keep the blister in the outer carton in order to protect from moisture.
Pretisni omot shranjujte v zunanji ovojnini, za zaščito pred vlago.
In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected.
V farmakoloških študijah niso odkrili medsebojnega delovanja med srčnim glikozidom ouabainom in pimobendanom.
Benazeprilat concentrations decline biphasically: the initial fast phase (t1/2 = 1.7 h) represents elimination of the free drug, while the terminal phase (t1/2 = 19 h) reflects the release of benazeprilat that was bound to ACE, mainly in the tissues.
Koncentracije benazeprilata upadajo dvofazno: začetna hitra faza (t1/2 = 1,7 ure) predstavlja izločanje prostega zdravila, medtem ko zaključna faza (t1/2 = 19 ur) odraža sproščanje benazeprilata, ki je bil vezan na ACE, predvsem v tkivih.
Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.
Nosečnice morajo biti posebej previdne, da preprečijo nenameren stik z usti, saj je bilo ugotovljeno, da zaviralci angiotenzinske konvertaze (ACE) vplivajo na nerojenega otroka med nosečnostjo pri ljudeh.
ADVICE ON CORRECT ADMINISTRATION FORTEKOR PLUS tablets can be divided into halves if needed.
NASVET O PRAVILNI UPORABI ZDRAVILA Tablete FORTEKOR PLUS lahko po potrebi razpolovimo na enaka dela.
Lactose monohydrate Magnesium stearate
Laktoza monohidrat Magnezijev stearat Koruzni škrob
Therefore the concurrent use of FORTEKOR PLUS with NSAIDs or any other medications with a hypotensive effect should be considered carefully before using such combinations.
Zato je treba sočasno uporabo zdravila FORTEKOR PLUS z nesteroidnimi protivnetnimi zdravili ali drugimi zdravili s hipotenzivnim učinkom obravnavati previdno, preden se takšna kombinacija uporabi.
A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.
Zmerno povečanje plazemskih koncentracij kreatinina po uporabi zaviralcev ACE je združljivo z zmanjšanjem glomerularne hipertenzije, ki jo povzročijo ta zdravila, in zato ni nujno razlog za prekinitev terapije, če ni prisotnih drugih znakov.
Repeated administration of benazepril hydrochloride leads to slight bioaccumulation of benazeprilat (R = 1.47), steady state being achieved within a few days (4 days).
Ponavljajoča se uporaba benazeprilijevega klorida vodi do rahle bioakumulacije benazeprilata (R = 1,47), pri čemer je dinamično ravnovesje doseženo v nekaj dneh (4 dni).
Benazepril and benazeprilat are extensively bound to plasma proteins (8590%), and in the tissues they are found mainly in the lung, liver and kidney.
Benazepril in benazeprilat se v veliki meri vežeta na plazemske beljakovine (85 - 90 %), v tkivih pa ju večinoma najdemo v pljučih, jetrih in ledvicah.
People with known hypersensitivity to pimobendan or benazepril hydrochloride should avoid contact with the veterinary medicinal product.
Osebe z znano preobčutljivostjo na pimobendan ali benazeprilijev klorid naj se izogibajo stiku z zdravilom.
It also exhibits a vasodilatory action through the inhibition of phosphodiesterase type III activity.
Ima tudi vazodilatatorni učinek skozi zaviranje aktivnosti fosfodiesteraze tipa III.
Benazeprilat is excreted via the biliary (54%) and urinary (46%) routes in dogs.
Benazeprilat se pri psih izloča z žolčem (54 %) in urinom (46 %).
Renal function and signs of hypotension (lethargy, weakness, etc) should be monitored closely and treated as necessary.
Delovanje ledvic in znake hipotenzije (letargija, slabost itd.) je treba skrbno spremljati in jih po potrebi zdraviti.
Therefore, benazepril blocks effects mediated by angiotensin II and aldosterone, including the vasoconstriction of arteries and veins, the retention of sodium and water by the kidney, and remodelling effects (including pathological cardiac hypertrophy and degenerative renal changes).
Benazepril zavira učinke angiotenzina II in aldosterona, vključno z vazokonstrikcijo tako arterij kot ven, zadrževanjem natrija in vode v ledvicah ter učinki preoblikovanja (vključno s patološko hipertrofijo srca in z degenerativnimi spremembami ledvic).
Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic or pulmonary stenosis).
Ne uporabite pri hipertrofični kardiomiopatiji ali kliničnih stanjih, pri katerih povečanje minutnega volumna srca ni mogoče zaradi funkcionalnih ali anatomskih razlogov (npr. aortne ali pljučne stenoze).
It increases the calcium sensitivity of cardiac myofilaments and inhibits phosphodiesterase (type III).
Povečuje občutljivost srčnih miofilamentov za kalcij in zavira fosfodiesterazo (tipa III).
Both tablet strengths are packaged in aluminium/aluminium blisters packaged into an outer cardboard box.
Obe jakosti tablet sta pakirani v pretisnih omotih iz aluminija/aluminija in zunanji kartonski škatli.
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the ß-antagonist propranolol.
Učinek pimobendana na povečanje krčljivosti srca je oslabljen v prisotnosti kalcijevega antagonista verapamila in antagonista β-receptorjev propranolola.
Any remaining half tablet should be placed back in the opened blister and stored (for a maximum of 1 day) in the original cardboard carton out of the sight and reach of children.
Morebitno neuporabljeno polovico tablete vedno vrnite v prazen pretisni omot in shranite (za največ en dan) v originalni zunanji ovojnini na varnem mestu izven dosega otrok.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports).
Najpogostejši neželeni učinek je v skupini naveden prvi, po naslednjem dogovoru: - zelo pogosti (med enim ciklom zdravljenja se pojavijo pri več kot 1 živali od 10 živali) - pogosti (pojavijo se pri 1 do 10 živalih od 100 živali) - občasni (pojavijo se pri 1 do 10 živalih od 1000 živali) - redki (pojavijo se pri 1 do 10 živalih od 10000 živali) - zelo redki (pojavijo se pri manj kot 1 živali od 10000 živali, vključujoč posamezne primere)
The combination of FORTEKOR PLUS and other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects.
Kombinacija zdravila FORTEKOR PLUS in drugih antihipertenzivnih zdravil (npr. zaviralcev kalcijevih kanalčkov, β-blokatorjev ali diuretikov), anestetikov ali pomirjeval lahko povzroči aditivne hipotenzivne učinke.
26 Rue de la Chapelle F-68330 Huningue
Elanco France S.A.S 26 Rue de la Chapelle F-68330 Huningue FRANCIJA
FORTEKOR PLUS is a fixed dose combination and should only be used in patients whose clinical signs are successfully controlled by administration of the same doses of the individual components (pimobendan and benazepril hydrochloride) given concurrently.
FORTEKOR PLUS je kombinirano zdravilo in se sme uporabljati samo pri živalih, pri katerih klinične znake uspešno nadzorujemo s sočasnim dajanjem enakih odmerkov posameznih komponent (pimobendana in benazeprilijevega klorida).
4.4 Special warnings for each target species
4.4 Posebna opozorila za vsako ciljno živalsko vrsto Jih ni.
Your veterinary surgeon may recommend to closely monitor kidney function and for signs of hypotension (lethargy, weakness etc) and treat these if necessary.
Veterinar lahko priporoči pozorno spremljanje delovanja ledvic in znakov hipotenzije (letargija, slabost itd.) ter zdravljenje, če je potrebno.
Interactions with potassium-preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out.
Medsebojnega delovanja z diuretiki, ki zadržujejo kalij, kot so spironolakton, triamteren ali amilorid, ni mogoče izključiti.
The tablets are bilayered, oval, white and light brown, and can be divided into halves along the score line.
Tablete so dvoplastne, ovalne, bele in svetlo rjave ter se lahko vzdolž zareze razpolovijo na enaka dela.
In dogs with congestive heart failure, benazepril hydrochloride and pimobendan have been given in combination with digoxin and diuretics without demonstrable adverse interactions.
Psom s kongestivnim srčnim popuščanjem so dajali benazeprilijev klorid in pimobendan v kombinaciji z digoksinom in diuretiki brez dokazljivega neželenega medsebojnega delovanja.
Do not use this veterinary medicinal product after the expiry date which is stated on the blister and carton after EXP.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na pretisnem omotu in škatli, za oznako »EXP«.
There is no significant difference in the pharmacokinetics of benazeprilat when benazepril hydrochloride is administered to fed or fasted dogs.
farmakokinetiki benazeprilata ni opazne razlike, če se benazeprilijev klorid daje nahranjenim ali teščim psom.
After the oral administration of FORTEKOR PLUS tablets at twice the recommended dose to dogs, peak levels of both compounds are attained rapidly (Tmax 0.5 h for benazepril hydrochloride and 0.85 h for pimobendan) with peak concentrations (Cmax) for benazepril hydrochloride of 35.1 ng/ml and 16.5 ng/ml for pimobendan.
Po peroralni uporabi tablet FORTEKOR PLUS pri psih v dvakratnem priporočenem odmerku so najvišje koncentracije obeh spojin hitro dosežene (Tmax 0,5 ure za benazeprilijev klorid in 0,85 ure za pimobendan), z najvišjo koncentracijo (Cmax) benazeprilijevega klorida 35,1 ng/ml in najvišjo koncentracijo pimobendana 16,5 ng/ml.
Do not use in cases of hypotension (low blood pressure), hypovolemia (low blood volume), hyponatraemia (low blood sodium levels) or acute renal (kidney) failure.
Ne uporabite pri hipotenziji (nizkem krvnem tlaku), hipovolemiji (premajhnem volumnu krvi), hiponatriemiji (nizki ravni natrija v krvi) ali akutni odpovedi ledvic.
Following oral administration of pimobendan alone the absolute bioavailability of the active ingredient is 60-63%.
Po peroralni uporabi samega pimobendana je absolutna biološka uporabnost zdravilne učinkovine 6063 %.
The efficacy and safety of the product has not been established in dogs below 2.5 kg bodyweight or under 4 months of age.
Učinkovitost in varnost zdravila nista bili ugotovljeni pri psih, lažjih od 2,5 kg ali mlajših od 4 mesecev.
In dogs with chronic kidney disease, benazepril may increase plasma creatinine concentrations at the start of therapy.
Pri psih s kronično boleznijo ledvic lahko benazepril poveča plazemske koncentracije kreatinina na začetku zdravljenja.
4.7 Use during pregnancy, lactation or lay
4.7 Uporaba v obdobju brejosti ali laktacije
For the treatment of congestive heart failure due to atrioventricular valve insufficiency or dilated cardiomyopathy in dogs.
Za zdravljenje kongestivnega srčnega popuščanja zaradi insuficience atrioventrikularne zaklopke ali dilatativne kardiomiopatije pri psih.
In cases of chronic kidney disease, it is recommended to check the dog's hydration status before starting therapy, and to monitor its plasma creatinine and blood erythrocyte counts during therapy.
V primerih kronične bolezni ledvic se priporoča, da pred začetkom zdravljenja preverite stanje hidracije psa ter da med zdravljenjem spremljate ravni kreatinina v plazmi in število eritrocitov v krvi.
METHOD AND ROUTE(S) OF ADMINISTRATION Oral use.
NAČIN IN POT(I) UPORABE
EU/2/15/185/001 (1 x 30 tablets, 1.25 mg/2.5 mg tablets) EU/2/15/185/002 (1 x 60 tablets, 1.25 mg/2.5 mg tablets) EU/2/15/185/003 (1 x 30 tablets, 5 mg/10 mg tablets) EU/2/15/185/004 (1 x 60 tablets, 5 mg/10 mg tablets)
EU/2/15/185/0001 (1 x 30 tablet, 1,25 mg/2,5 mg tablete) EU/2/15/185/0002 (1 x 60 tablet, 1,25 mg/2,5 mg tablete) EU/2/15/185/0003 (1 x 30 tablet, 5 mg/10 mg tablete) EU/2/15/185/0004 (1 x 60 tablet, 5 mg/10 mg tablete)
The volume of distribution at steady state is 2.6 l/kg after intravenous administration of pimobendan alone, indicating that pimobendan is distributed readily into the tissues.
Volumen porazdelitve v stanju dinamičnega ravnovesja je 2,6 l/kg po intravenskem dajanju samega pimobendana, kar kaže na to, da se pimobendan hitro porazdeli v tkiva.
It is not known if benazepril is secreted into the milk of lactating bitches.
Ni znano, ali benazepril pri psicah v obdobju laktacije prehaja v mleko.
Laboratory studies in rats have shown that pimobendan is excreted into milk.
Z laboratorijskimi študijami na podganah je bilo dokazano, da se pimobendan izloča z mlekom.
Each tablet contains 5 mg pimobendan and 10 mg benazepril hydrochloride.
Vsaka tableta vsebuje 5 mg pimobendana in 10 mg benazeprilijevega klorida.
The tablets are breakable along the score line.
Tablete se prelomijo vzdolž zareze.
Peak benazeprilat levels are seen after 1.9 h with peak concentrations (Cmax) of 43.4 ng/ml.
Najvišje ravni benazeprilata so dosežene po 1,9 ure, ko je najvišja koncentracija (Cmax) 43,4 ng/ml.
In rare cases transient diarrhoea, anorexia or lethargy have been observed.
V redkih primerih so opazili prehodno drisko, anoreksijo ali letargijo.
Body weight (kg) of dog
Telesna masa psa (kg)
Pack Sizes
Velikosti pakiranj
PHARMACEUTICAL FORM Tablets
FARMACEVTSKA OBLIKA Tablete.
EU/2/15/185/001 (1 x 30 tablets, 1.25 mg/2.5 mg) EU/2/15/185/002 (1 x 60 tablets, 1.25 mg/2.5 mg) EU/2/15/185/003 (1 x 30 tablets, 5 mg/10 mg)
EU/2/15/185/0001 (1 x 30 tablet, 1,25 mg/2,5 mg) EU/2/15/185/0002 (1 x 60 tablet, 1,25 mg/2,5 mg) EU/2/15/185/0003 (1 x 30 tablet, 5 mg/10 mg) EU/2/15/185/0004 (1 x 60 tablet, 5 mg/10 mg)
Pimobendan is oxidatively demethylated to its major active metabolite, O-desmethyl pimobendan.
Pimobendan se oksidativno demetilira v glavni aktivni metabolit O-desmetilpimobendan.
The safety of FORTEKOR PLUS has not been tested in breeding, pregnant or lactating dogs.
Varnost zdravila FORTEKOR PLUS ni bila preizkušena pri psih, ki so namenjeni za vzrejo ali so v obdobju brejosti ali laktacije.
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.
Ne uporabite pri hipotenziji, hipovolemiji, hiponatriemiji ali akutni odpovedi ledvic.